After acquiring a majority stock stake in a pharmaceutical firm, Shineco Inc. (Nasdaq: SISI) is ascending the charts today, up 12.94% to trade at $1.23 at the most recent check.
What assets has SISI purchased?
Changzhou Biowin Pharmaceutical Co., Ltd. (“CBP”) is a Chinese biotechnology company that focuses on in-vitro diagnostic product research and development (“R&D”) and high-tech biomedical product manufacturing. On October 21, 2022, Shineco (SISI) announced that through its wholly-owned subsidiary, Shineco Life Science, it entered into a Stock Purchase Agreement (the “Agreement”) to purchase 51% of the issued equity interest of CBP. This deal will cost more than $10 million, which will be paid in cash and Shineco ordinary shares. A key component of SISI’s business plan to enter the Point-of-Care Testing (“POCT”) market is this purchase.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
As a component of in vitro diagnostics (IVD), POCT is a detection strategy that employs portable diagnostic tools and supplementary test reagents to conduct the test on-site and get a quick result. Two examples of POCT are the COVID-19 and monkeypox detection reagents, which offer quick, easy, cost-effective, and efficient detection procedures and may be extensively used in the quickly expanding market. The POCT market has had 26% compound annual growth over the past few years. Globally, POCT held the top spot in 2021 with a market share of 29% and an IVD market share of US$117 billion.
In just a few years, CBP has established an ISO 13485 certified manufacturing facility, a quality control system for related products, and the following POCT related technology platforms: colloidal gold immunoassay, fluorescence immunoassay, and loop-mediated isothermal amplification (LAMP) nucleic acid detection. CBP has also developed 16 categories of 55 products in the field of rapid diagnostics under the leadership of founder and Chairman Dr. Marvin Liu. 33 certificates for the registration of Vitro diagnostic reagents, 21 EU CE certifications, and 8 products that have finished R&D and are undergoing product registration, covering cardiovascular diseases, infectious diseases, diabetes, digestive diseases, and other fields, have all been obtained by CBP.
How will the acquisition help SISI?
This purchase signifies Shineco’s (SISI) official entry into the POCT industry and is a significant turning point in the company’s value-chain upgrading plan. The partnership with CBP created a closed loop in Shineco’s upstream and downstream supply chain. The dominant market position of CBP will assist SISI as well. Additionally, patients will be able to identify crucial illnesses early and boost the cure rate while lowering treatment costs because of the affordability, effectiveness, and simplicity of the POCT solutions.